BACKGROUND: The role of eicosanoids, including leukotrienes (LTs) and prostaglandins (PGs), in chronic obstructive pulmonary disease (COPD) is uncertain. The aim of this study was to investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), a non-invasive method of collecting airway secretions, in patients with stable mild to moderate COPD, and to show possible differences in their concentrations compared with control subjects. METHODS: LTB(4), LTE(4), PGE(2), PGD(2)-methoxime, PGF(2alpha), and thromboxane B(2) (TxB(2)) were measured in EBC in 15 healthy ex-smokers, 20 steroid naïve patients with COPD who were ex-smokers, and in 25 patients with COPD who were ex-smokers and who were treated with inhaled corticosteroids. The study was of cross sectional design and all subjects were matched for age and smoking habit. RESULTS: LTB(4) and PGE(2) concentrations were increased in steroid naïve (LTB(4): median 100.6 (range 73.5-145.0) pg/ml, p<0.001; PGE(2): 98.0 (range 57.0-128.4) pg/ml, p<0.001) and steroid treated patients with COPD (LTB(4): 99.0 (range 57.9-170.5) pg/ml, p<0.001; PGE(2): 93.6 (range 52.8-157.0) pg/ml, p<0.001) compared with control subjects (LTB(4): 38.1 (range 31.2-53.6) pg/ml; PGE(2): 44.3 (range 30.2-52.1) pg/ml). Both groups of patients had similar concentrations of exhaled LTB(4) (p=0.43) and PGE(2) (p=0.59). When measurable, LTE(4) and PGD(2)-methoxime concentrations were similar in COPD patients and controls, whereas PGF(2alpha) concentrations were increased in the former. TxB(2)-LI was undetectable in any of the subjects. CONCLUSIONS: There is a selective increase in exhaled LTB(4) and PGE(2) in patients with COPD which may be relatively resistant to inhaled corticosteroid therapy.
BACKGROUND: The role of eicosanoids, including leukotrienes (LTs) and prostaglandins (PGs), in chronic obstructive pulmonary disease (COPD) is uncertain. The aim of this study was to investigate whether eicosanoids are measurable in exhaled breath condensate (EBC), a non-invasive method of collecting airway secretions, in patients with stable mild to moderate COPD, and to show possible differences in their concentrations compared with control subjects. METHODS:LTB(4), LTE(4), PGE(2), PGD(2)-methoxime, PGF(2alpha), and thromboxane B(2) (TxB(2)) were measured in EBC in 15 healthy ex-smokers, 20 steroid naïve patients with COPD who were ex-smokers, and in 25 patients with COPD who were ex-smokers and who were treated with inhaled corticosteroids. The study was of cross sectional design and all subjects were matched for age and smoking habit. RESULTS:LTB(4) and PGE(2) concentrations were increased in steroid naïve (LTB(4): median 100.6 (range 73.5-145.0) pg/ml, p<0.001; PGE(2): 98.0 (range 57.0-128.4) pg/ml, p<0.001) and steroid treated patients with COPD (LTB(4): 99.0 (range 57.9-170.5) pg/ml, p<0.001; PGE(2): 93.6 (range 52.8-157.0) pg/ml, p<0.001) compared with control subjects (LTB(4): 38.1 (range 31.2-53.6) pg/ml; PGE(2): 44.3 (range 30.2-52.1) pg/ml). Both groups of patients had similar concentrations of exhaled LTB(4) (p=0.43) and PGE(2) (p=0.59). When measurable, LTE(4) and PGD(2)-methoxime concentrations were similar in COPDpatients and controls, whereas PGF(2alpha) concentrations were increased in the former. TxB(2)-LI was undetectable in any of the subjects. CONCLUSIONS: There is a selective increase in exhaled LTB(4) and PGE(2) in patients with COPD which may be relatively resistant to inhaled corticosteroid therapy.
Authors: Richard M Effros; Kelly W Hoagland; Mark Bosbous; Daniel Castillo; Bradley Foss; Marshall Dunning; Meir Gare; Wen Lin; Feng Sun Journal: Am J Respir Crit Care Med Date: 2002-03-01 Impact factor: 21.405
Authors: P Montuschi; J V Collins; G Ciabattoni; N Lazzeri; M Corradi; S A Kharitonov; P J Barnes Journal: Am J Respir Crit Care Med Date: 2000-09 Impact factor: 21.405
Authors: Neil D Gross; Jay O Boyle; Jason D Morrow; Myles K Williams; Chaya S Moskowitz; Kotha Subbaramaiah; Andrew J Dannenberg; Anna J Duffield-Lillico Journal: Clin Cancer Res Date: 2005-08-15 Impact factor: 12.531
Authors: S Patrick Nana-Sinkam; Jong Deog Lee; Sylk Sotto-Santiago; Robert S Stearman; Robert L Keith; Qamrul Choudhury; Carlyne Cool; Jane Parr; Mark D Moore; Todd M Bull; Norbert F Voelkel; Mark W Geraci Journal: Am J Respir Crit Care Med Date: 2007-01-25 Impact factor: 21.405
Authors: Angie L Hertz; Andrew T Bender; Kimberly C Smith; Mark Gilchrist; Paul S Amieux; Alan Aderem; Joseph A Beavo Journal: Proc Natl Acad Sci U S A Date: 2009-12-03 Impact factor: 11.205
Authors: Patrick G Morris; Xi Kathy Zhou; Ginger L Milne; Daniel Goldstein; Laura C Hawks; Chau T Dang; Shanu Modi; Monica N Fornier; Clifford A Hudis; Andrew J Dannenberg Journal: Cancer Prev Res (Phila) Date: 2013-03-26
Authors: Gautam Damera; Hengjiang Zhao; Miao Wang; Michael Smith; Christopher Kirby; William F Jester; John A Lawson; Reynold A Panettieri Journal: Am J Physiol Lung Cell Mol Physiol Date: 2009-02-06 Impact factor: 5.464